Targeting Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Based on Risk of Intracranial Hemorrhage or Poor Functional Outcome | Zendy

William Whiteley | Zendy; Douglas Thompson | Zendy; Gordon Murray | Zendy; Geoff Cohen | Zendy; Richard I. Lindley | Zendy; Joanna M. Wardlaw | Zendy; Peter Sandercock | Zendy

Open Access

Targeting Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Based on Risk of Intracranial Hemorrhage or Poor Functional Outcome

Author(s) -

William Whiteley,

Douglas Thompson,

Gordon Murray,

Geoff Cohen,

Richard I. Lindley,

Joanna M. Wardlaw,

Peter Sandercock

Publication year - 2014

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.113.004362

Subject(s) - medicine , plasminogen activator , recombinant tissue plasminogen activator , stroke (engine) , tissue plasminogen activator , intracerebral hemorrhage , ischemic stroke , intracranial hemorrhages , thrombolysis , recombinant dna , brain ischemia , cardiology , ischemia , surgery , subarachnoid hemorrhage , modified rankin scale , myocardial infarction , mechanical engineering , engineering , biochemistry , chemistry , gene

Intravenous recombinant tissue-type plasminogen activator (r-tPA), despite a risk of early symptomatic intracranial hemorrhage (sICH), is of net clinical benefit to acute stroke patients. We tested if predictive models could identify patients least likely to be harmed by sICH or those who gained no net benefit.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research